Month: September 2021

TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Firm Capital Property Trust (“FCPT” or the “Trust”) (TSXV : FCD.UN) is pleased to announce that at the annual and special meeting (the “Meeting”) of unitholders held earlier today, all nominees were elected as trustees of the Trust, as follows:Nominee Votes “For” % Votes “For” Votes “No” % of Votes “No” Votes “Abstain” % of Votes “Abstain”Geoffrey Bledin 6,056,565 94.5%   – – 350,924 5.5%  Eli Dadouch 6,023,965 94.0%   – – 383,524 6.0%  Jeffrey Goldfarb 6,033,665 94.2%   – – 373,824 5.8%  Stanley Goldfarb 6,036,765 94.2%   – – 370,724 5.8%  Victoria Granovski 6,027,165 94.1%   – – 380,324 5.9%  Jonathan Mair 6,040,565 94.3%   – – 366,924 5.7%  Robert McKee 6,033,765 94.2%   – – 373,724 5.8%  Sandy...

The All-New Axis T250The Axis T250 gives those boaters looking for more space and storage the largest Axis yet, complete with the intuitiveness, performance and value that have made Axis the fastest-growing towboat company.LOUDON, Tenn., Sept. 09, 2021 (GLOBE NEWSWIRE) — The totally-new Axis T250 makes history as the first 25-foot boat produced by the cutting-edge Axis brand. With bold styling, spacious seating, proven technology and signature Axis performance, the T250 is ready for all your friends and family. Axis is a brand that was born out of customer demand and the T250 is no exception. We took customer input to present our boaters something bigger than ever before for the Axis line. The Axis T250 gives those boaters looking for more space and storage the largest Axis yet, complete with the intuitiveness,...

Caledon, Ontario, Sept. 09, 2021 (GLOBE NEWSWIRE) — CardioGenics Holdings INC. (OTC PINK: CGNH) announced on September 3, 2021 a record date of September 13, 2021 for its dividend distribution of 22.5 million shares of Covidgenics, a private Canadian company. A new record date for the distribution will be announced, following completion of all necessary regulatory requirements, within the next few days. About CardioGenics Holdings Inc. The Company is focused on technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary point-of-care immuno-analyzer, which will be capable of running 200+immunoassay diagnostic tests, such as cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary...

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) — Outbrain Inc. (“Outbrain”) (Nasdaq: OB), a leading recommendation platform for the open web, announced today that its management team will participate in the following upcoming investor conferences and events: Citi’s 2021 Global Technology Virtual ConferenceSeptember 14, 2021Fireside Chat – 12:10 PM Eastern Time Jefferies Virtual Software ConferenceSeptember 15, 2021Presentation – 11:30 AM Eastern Time Jefferies Israel Innovation SummitSeptember 30, 2021Panel and Presentation A live webcast and replay of the fireside chat and presentations will be featured on Outbrain’s investor relations website at https://investors.outbrain.com/. About Outbrain Outbrain (Nasdaq: OB) is a leading recommendation platform for the open web. Our technology enables 10 billion daily recommendations to consumers...

Commitments from Morgan Stanley, Goldman Sachs, Jefferies and J.P. Morgan SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) — Oportun Financial Corporation (NASDAQ: OPRT), an A.I.-driven financial services and technology company that provides hardworking people with access to responsible and affordable credit, today announced the closing of a new warehouse credit facility of $600 million, backed by a portion of Oportun’s unsecured and secured personal loans. The new facility includes commitments from Morgan Stanley Bank, N.A., Goldman Sachs Bank USA, Jefferies Funding LLC, and JPMorgan Chase Bank, N.A. “Oportun has developed a novel approach to addressing financial inclusion, which is a serious and significant societal issue that other companies have struggled to address at scale,” said Oportun CEO Raul Vazquez. “Our lenders...

LEXINGTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel—a molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infections—is capable of detecting the Mu (B.1.621) and Iota (B.1.526) variants of the SARS-CoV-2 virus, which were recently confirmed to be present in the United States. “We are proud to announce our technology is capable of detecting additional COVID-19 variants including Mu and Iota, enabling healthcare providers with the confidence to make more informed decisions about their patients’ health,” said T2 Biosystems’ Chairman and CEO, John Sperzel. Like the variants identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1), the...

NASHVILLE, Tenn., Sept. 09, 2021 (GLOBE NEWSWIRE) — Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”) today provided a business update and supplemental information. The supplement can be located on the Company’s website under Investor Relations Home / News & Events / Presentations & Transcripts (http://ir.rymanhp.com/index.php/events-and-presentations/presentations). About Ryman Hospitality Properties, Inc. Ryman Hospitality Properties, Inc. (NYSE: RHP) is a leading lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. The Company’s core holdings include a network of five of the top 10 largest non-gaming convention center hotels in the United States based on total indoor meeting space. These convention center...

BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. (“Introspect”), today announced a usability study of Introspect’s digital therapeutic (DTx) app technology in support of standard of care ketamine therapy for patients with treatment resistant depression (TRD) in collaboration with Kadima Neuropsychiatry. TRD impacts 100 million people globally, close to a third of the 300 million diagnosed with depression, many of whom are geographically restricted in their ability to access in-person psychological care. Introspect’s DTx app approach to supported treatment in mental health will be integrated...

BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1 Gangliosidosis and Morquio B Disease. GM1 Virtual Community ConferenceDate: Tuesday, September 14thTime: 2:00pm PT/5:00pm ETPresenter: Manolo Bellotto, Ph.D., General Manager and PresidentTo register to attend the conference visit https://registration.socio.events/e/gm1 Morquio B, also known as Mucopolysaccharidosis type IV (MPS IV), is a...